What is NewAmsterdam Pharma Company N.V. Ordinary Shares?
, a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
, a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 2.42B.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.
| Shares sold | Shares bought | |
|---|---|---|
| 0-3months | 0 | 0 |
| 3-6months | 0 | 0 |
| 6-9months | 91,122,805 shares $36.6M | 0 |
| 9-12months | 10344,128 shares $11.8M | 0 |